{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:35:57Z","timestamp":1789785357576,"version":"4.0.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Somapacitan is a long-acting growth hormone (GH) derivative approved for once-weekly treatment of adult GH deficiency (AGHD). This study aimed to evaluate the efficacy and safety of somapacitan and daily GH in Japanese individuals with AGHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This subgroup study included the 34-week main period of the multinational, randomized, parallel-group, phase 3 trial, REAL 1 (NCT02229851). Participants received once-weekly somapacitan or daily GH (Norditropin\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ), both administered subcutaneously. Investigators and trial sites were blinded. A total of 36 Japanese GH-na\u00efve individuals with AGHD were allocated to somapacitan or daily GH (excluding the placebo group of the global trial). Endpoints included change in truncal fat percentage to week 34 measured using dual-energy x-ray absorptiometry, as well as other body composition measures. Insulin-like growth factor I standard deviation score values were used for dose titration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 36 Japanese individuals were included (18 and 18 in the somapacitan and daily GH group, respectively). 35 completed the main period (34 weeks). Mean (SD) change from baseline to week 34 in truncal fat percentage was -2.23 (2.50) %-points in the somapacitan group and -2.12 (4.21) %-points in the daily GH group. Other body composition measures also improved in both groups, including reduced visceral fat and increased lean body mass. Somapacitan was well tolerated, with a safety profile similar to daily GH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Japanese treatment-na\u00efve individuals with AGHD, once-weekly somapacitan demonstrated similar efficacy and safety to daily GH after 34 weeks of treatment. Somapacitan provides an effective alternative to daily GH in AGHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      , identifier NCT02229851.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1534891","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:10:27Z","timestamp":1738887027000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Fumio","family":"Otsuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H\u00f8jby","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Sv\u00e6rke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudmundur","family":"Johannsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1817346","article-title":"Pathogenesis and diagnosis of growth hormone deficiency in adults","volume":"380","author":"Melmed","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13382","article-title":"Growth hormone deficiency in adults with hypopituitarism-What are the risks and can they be eliminated by therapy","volume":"290","author":"Johannsson","year":"2021","journal-title":"J Intern Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1006","article-title":"Impairment of anaerobic capacity in adults with growth hormone deficiency","volume":"100","author":"Chikani","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1530\/EJE-07-0013","article-title":"Mortality and GH deficiency: a nationwide study","volume":"157","author":"Stochholm","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4158\/EP.14.2.143","article-title":"Compliance and persistence in pediatric and adult patients receiving growth hormone therapy","volume":"14","author":"Rosenfeld","year":"2008","journal-title":"Endocr Pract"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0111","article-title":"Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations","volume":"174","author":"Christiansen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1991","article-title":"Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency","volume":"101","author":"Rasmussen","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-1073","article-title":"Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial","volume":"178","author":"Johannsson","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14273","article-title":"Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone","volume":"93","author":"Otsuka","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cen.2017.87.issue-4","article-title":"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial","volume":"87","author":"Battelino","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad183","article-title":"Weekly somapacitan in GH deficiency: 4-year efficacy, safety and treatment\/disease burden results from REAL","volume":"108","author":"S\u00e4vendahl","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac513","article-title":"Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial","volume":"107","author":"Miller","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa049","article-title":"Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial","volume":"105","author":"Johannsson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3060","article-title":"Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays","volume":"99","author":"Friedrich","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30084-1","article-title":"Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement","volume":"7","author":"Neeland","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/cen.15025","article-title":"Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial","volume":"100","author":"Mori","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"EP704","DOI":"10.1530\/endoabs.41.EP704","article-title":"Concomitant medication in growth hormone (GH)-treated patients with adult GH deficiency (AGHD): an analysis from NordiNet\u00ae International Outcome Study (IOS)","volume":"41","author":"H\u00f6ybye","year":"2016","journal-title":"Endocrine Abstracts"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2019-0405","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care","volume":"25","author":"Yuen","year":"2019","journal-title":"Endocr Pract"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1179\/acb.2010.002","article-title":"Treatment of adult growth hormone deficiency: who, why and how? A review","volume":"65","author":"Alexopoulou","year":"2010","journal-title":"Acta Clin Belg"},{"key":"B20","article-title":"Plain language summary for \u201cEfficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial\u201d. figshare","author":"Otsuka","year":"2025","journal-title":"Journal contribution"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1534891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T02:09:29Z","timestamp":1750126169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1534891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":20,"alternative-id":["10.3389\/fendo.2025.1534891"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1534891","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"article-number":"1534891"}}